Salmeterol-d3 (xinafoate) Reference: 27191-1 An internal standard for the quantification of salmeterol by GC- or LC-MS
CB-52 Reference: 10010117-5 A stable analog of Δ9-THC and AEA; exhibits high-affinity for the CB1 and CB2 receptors (Ki = 210 and 30 nM, respectively); behaves primarily as a CB1 receptor partial agonist and a CB2 receptor neutral antagonist in vitro
Salmeterol-d3 (xinafoate) Reference: 27191-500 An internal standard for the quantification of salmeterol by GC- or LC-MS
CB-52 Reference: 10010117-50 A stable analog of Δ9-THC and AEA; exhibits high-affinity for the CB1 and CB2 receptors (Ki = 210 and 30 nM, respectively); behaves primarily as a CB1 receptor partial agonist and a CB2 receptor neutral antagonist in vitro
C18 Phytoceramide-d3 (t18:0/18:0-d3) Reference: 27199-1 An internal standard for the quantification of C18 phytoceramide by GC- or LC-MS
AM1241 Reference: 10010118-1 A CB2 receptor agonist; selective for CB2 over CB1 (Kis = 7.1 and 580 nM); considered a protean agonist because it has neutral antagonist and partial agonist activity, depending on the assay utilized; acts in a species-dependent manner in vitro, acting as an agonist at human CB2 receptors (EC50 = 190 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 216 and 463 nM, respectively); produces antinociception to thermal stimuli in rat hindpaw; neuroprotective, preventing Gp120-induced apoptosis in vitro and increasing survival and differentiation of neural progenitor cells; increases hippocampal neurogenesis in GFAP/Gp120 transgenic mice when administered at a dose of 10 mg/kg daily for ten days; delays motor impairment in a murine model of ALS